Skip to content
askbio-logo Clinical Trials
  • Careers
  • News
  • Contact
  • Clinical Trials
  • For Patients
    • For Patients
    • Diseases
    • Clinical Trials
    • Patient Stories
    • Advocacy Partners
  • Our Focus
    • Genetic Diseases
    • AAV Gene Therapy
    • Pipeline
    • Research Areas
  • For Researchers
    • Discovery Program
    • Science & Technology
    • Partners & Collaborators
    • Resources
  • Our Technology
    • AAV Technology Platform
    • Capsids
    • Promoters
    • Pro10™
    • neDNA™
    • Manufacturing
  • About Us
    • Who we are
    • The Jude Samulski Story
    • Leadership Team
    • Board of Directors
    • Foundation
  • News
    • Careers
    • News
    • Contact
  • For Patients
    • For Patients
    • Diseases
    • Clinical Trials
    • Patient Stories
    • Advocacy Partners
  • Our Focus
    • Genetic Diseases
    • AAV Gene Therapy
    • Pipeline
    • Research Areas
  • For Researchers
    • Discovery Program
    • Science & Technology
    • Partners & Collaborators
    • Resources
  • Our Technology
    • AAV Technology Platform
    • Capsids
    • Promoters
    • Pro10™
    • neDNA™
    • Manufacturing
  • About Us
    • Who we are
    • The Jude Samulski Story
    • Leadership Team
    • Board of Directors
    • Foundation
  • News
    • Careers
    • News
    • Contact
  • Careers
  • News
  • Contact
  • Clinical Trials

About: SocialMedia

Posts by SocialMedia:

  • AskBio and Touchlight Restructure Joint Venture Posted on February 14, 2022 (February 14, 2022) by Social Media in News
  • AskBio Names Philip Dana Chief Human Resources Officer Posted on January 10, 2022 (January 10, 2022) by Social Media in News
  • AskBio Receives FDA Fast Track Designation for LION-101, a Novel Investigational AAV Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) Posted on June 28, 2021 (June 28, 2021) by Social Media in News
  • AskBio Announces IND for LION-101, a Novel Investigational AAV Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9), Cleared to Proceed by U.S. FDA Posted on May 25, 2021 (May 25, 2021) by Social Media in News
  • AskBio Named 2021 Life Sciences Awards Company of the Year Winner by Triangle Business Journal Posted on May 21, 2021 (May 21, 2021) by Social Media in News&Uncategorized
  • ASGCT 2021 | Virtual Meeting Posted on May 7, 2021 (May 10, 2021) by Social Media in Event
  • AskBio Announces Presentations at Upcoming American Society of Gene and Cell Therapy’s 24th Annual Meeting Posted on May 6, 2021 (May 16, 2022) by Social Media in News
  • Selecta Biosciences and AskBio Announce Updates to Methylmalonic Acidemia (MMA-101) Program Posted on April 29, 2021 (January 7, 2022) by Social Media in News
  • AskBio Appoints Tim Trost as Chief Financial Officer Posted on May 19, 2020 (May 22, 2020) by Social Media in News
  • AskBio Acquires BrainVectis to Expand its Clinical Pipeline for Neurodegenerative Diseases Posted on April 22, 2020 (August 6, 2020) by Social Media in News
  • 1
  • 2
  • »
askbio-logo
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Inquiries

  • Media Center
  • Contact Us
  • Careers
  • Corporate Support

US Headquarters

20 T.W. Alexander Drive
Suite 110
Research Triangle Park,
NC 27709, USA

+1 (919) 561-6210

AskBio UK

Roslin Innovation Center
Easter Bush Campus
Edinburgh, EH25 9RG
Scotland

+44 (0) 131 651 9662

Mailing Address

PO Box 12848
Durham, NC 27709

© 2024 AskBio Inc. (AskBio)

  • Privacy and Terms
  • Terms and conditions of use